Domestic market growth helps Indian pharma companies offset US pricing pressure: Fitch

Domestic market growth helps Indian pharma companies to offset US pricing pressure: Fitch

11:05 AM, 3rd June 2019
Generic drugs. (File photo)
Generic drugs. (File photo)

MUMBAI, INDIA/SINGAPORE: A report from Fitch Ratings Inc states that the rising revenues in the domestic market helped Indian pharmaceutical companies counterbalance the ongoing pricing pressure on generic drugs in the US in the financial year ended 31 March 2019 (FY19).

The US and India are the two key markets served by Indian pharmaceutical companies, which sell predominantly generic drugs. Many of the leading pharmaceutical companies - including Glenmark Pharmaceuticals Ltd (BB/Stable), Lupin Limited (Lupin) and Dr Reddy's Laboratories Ltd (DRL) - reported double-digit growth in their domestic sales, supported by robust growth in chronic categories such as cardiac, anti-diabetics and respiratory, which in turn supported overall industry growth of 11% during FY19.

By contrast, growth in the US market remained subdued for many Indian drug-makers, as consolidation of pharma distributors and a faster pace of approvals of new generic drugs by the US Food and Drug Administration (USFDA) has resulted in continued pressure on generic drug pricing over the last few years. Companies with a solid record of compliance with the current Good Manufacturing Practices (CGMP) of the USFDA - such as Glenmark - have experienced less severe revenue pressure as they managed to avoid regulatory disruption to existing business, and launched new products leveraging on timely approvals from their Abbreviated New Drug Application (ANDA) pipeline. Similarly, the ramp-up of speciality portfolio and generic launches with "First-to-File" exclusivity helped some of the larger companies boost their US revenues in 4QFY19.

Overall, revenue growth was in the mid- to high-single-digits for Glenmark, Lupin and DRL during FY19. There was also healthy growth in Europe and Russia as well as in Active Pharmceutical Ingredient (API) sales. Operating margins were weaker for most companies due to the combined effect of pricing pressure in the US as well as an ongoing focus on R&D spending in order to bolster their presence in novel and speciality drugs.

Fitch expects companies with an appropriate CGMP compliance record to be better placed to mitigate the effect of pricing pressure in the US. We believe Indian drug-makers' efforts to expand their presence in speciality and novel drugs will help to reduce their dependence on the intensely competitive generic business. However, we do not expect a meaningful shift away from generics during FY20.

Fitch believes that Glenmark's ANDA pipeline will help counterbalance pricing pressure in the US, while growth in India and other geographies will help achieve moderate level of revenue growth and largely stable profitability. Glenmark aims to invest actively in R&D to develop its novel and speciality pipeline. However, we expect no significant impact on credit metrics as the company aims to fund this by disposals of non-core products and by sharing development costs with partners.

Jubilant Pharma Limited (JPL, BB-/Stable) is focused on speciality pharma segments, with a very limited presence in generic formulations. We feel this will help to sustain its operating performance and credit metrics in line with our expectations despite the adverse USFDA developments recently in their generic focused plants in India.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Sadananda Gowda joins Modi 2.0 team as Minister of Chemical and Fertilisers

DELHI, INDIA: Karnataka MP D V Sadananda Gowda has been allocated the Ministry of Chemical and Fertilisers in the second term of Prime Minister Narend ...

Read more
ADNOC marks Modi’s swearing-in as prime minister of India

DUBAI, UAE: The Abu Dhabi National Oil Company (ADNOC) has marked Narendra Modi’s swearing in ceremony as the Prime Minister of India. Symbolis ...

Read more
Researchers develop new water purifying device inspired by a rose

AUSTIN, US: The rose may be one of the most iconic symbols of the fragility of love in popular culture, but now the flower could hold more than just s ...

Read more
Researchers develop innovative, more cost-effective method to make drugs

WEST LAFAYETTE, US: The Food and Drug Administration wants the pharmaceutical industry to get away from making drugs using the traditional b ...

Read more
Newly created bioplastic for food packaging degrades in two years

KAUNAS, LITHUANIA: Group of scientists at Kaunas University of Technology (KTU). Lithuania have created biodegradable plastic, which decays in a compo ...

Read more
What Modi 2.0 could mean for the Indian pharma industry?

NEW DELHI, INDIA: The Rs 1,20,000 crore plus Indian pharma industry has been through a churn in the past five years. Over the last year, it has finall ...

Read more